Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06433505 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT06433505 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 24 participants.
The verdict
NCT06433505, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The objective of this study is to assess the pharmacokinetics (PK) and absolute bioavailability of BMS-986365 and to investigate the PK, metabolite profile, routes and extent of elimination, and mass balance of BMS-986365.
Interventions
- DRUG BMS-986365
- DRUG [14C] BMS-986365
- DRUG [14C] BMS-986409 + BMS-986410
- DRUG [14C] BMS-986410 + BMS-986409
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-05-30 |
| Est. Completion | 2025-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06433505
The ClinicalTrials.gov registry entry for NCT06433505 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which BMS-986365 is the first listed.
NCT06433505 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06433505 about?
NCT06433505 is a clinical study titled "A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants". The objective of this study is to assess the pharmacokinetics (PK) and absolute bioavailability of BMS-986365 and to investigate the PK, metabolite profile, routes and extent of elimination, and mass balance of BMS-986365.
What is the current status of trial NCT06433505?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-05-30. Estimated completion is 2025-02-28.
What interventions are being tested in trial NCT06433505?
The interventions under investigation include: BMS-986365 (DRUG), [14C] BMS-986365 (DRUG), [14C] BMS-986409 + BMS-986410 (DRUG), [14C] BMS-986410 + BMS-986409 (DRUG).
Who is sponsoring clinical trial NCT06433505?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.